Immunogenicity of Chitosan-Based Non-invasive Vaccine Strategy Against Mycobacterium tuberculosis

Abstract

Background: In spite of Bacillus Calmette-Guerin (BCG) vaccination, still tuberculosis caused by Mycobacterium tuberculosis remains a problematic impediment that requires perspective management. The aim of this study was to evaluate the immunogenicity of chitosan nanoparticles containing recombinant mycobacterial proteins and adjuvant in the Balb/C mice through a non-invasive nasal inhalation delivery route and measure the level of cytokines interferon gamma (IFN-γ), interleukin-4 (IL-4), and IL-17. Methods: Thirty mice in five different groups were vaccinated through inhalation with compounds set in different combinations. Two weeks after the last nasal delivery, IFN-γ, IL-4, and IL-17 were measured in spleen cell culture supernatants. Results: The IFN-γ and IL-17 concentrations were found to increase in the groups that received chitosan nanoparticles containing protein and adjuvant alone or as a BCG booster. Our study showed that the chitosan nanoparticle containing protein and adjuvant induced a Th1 response. However, the groups that first received BCG and then chitosan nanoparticles containing protein and adjuvant had the greatest Th1 response in terms of IFN-γ and IL-17 production in all the groups. Conclusion: Our findings showed that the vaccine designed to be administered through the nasal mucosa well stimulates cellular immunity and enhances the BCG vaccine’s effectiveness.

Keywords

• nasal mucosa
• vaccine
• bacillus calmette-guerin
• chitosan
• tuberculosis
• immunogenicity
• mycobacterium tuberculosis
• delivery system